Price
No data yet.
Social Signal Score
Revenue
$1.92M+68.56%Company Profile
- CEO
- Paul Baehr
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- -0.04
- Country
- CA
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 5.42
Financials
Revenue
$1.92M+68.6%Net Income
$49.7K-66.6%EBITDA
$314.4K+210.4%Free Cash Flow
$157.2K+165.7%EPS (diluted)
$0.00-80.0%Shares Outstanding (diluted)
24.51M-0.8%Operating Expenses
$1.21MCash & Debt
$8.69MReturn of Capital
$126.2KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2023 | $7.49M | $3.89M | $0.16 |
| 2022 | $7.89M | $1.67M | $0.07 |
| 2021 | $5.31M | $761.5K | $0.03 |
| 2020 | $5.21M | $965.7K | $0.04 |
| 2019 | $4.31M | $-1.27M | $-0.05 |
| 2018 | $4.73M | $-95.2K | $-0.00 |
| 2017 | $5.33M | $2.98M | $0.12 |
| 2016 | $4.11M | $100.6K | $0.00 |
| 2015 | $3.49M | $209.6K | $0.01 |
| 2014 | $3.94M | $-480.7K | $-0.02 |
| 2013 | $3.97M | $40.4K | $0.00 |
| 2012 | $2.92M | $230.0K | $0.01 |
| 2011 | $2.24M | $103.6K | $0.00 |
| 2010 | $2.63M | $506.4K | $0.02 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IBXNF's reported EPS growth of 17.3% a year over 13 years.
- EPS in 5 years
- $0.35
- Implied price
- $2.44
- Return from $1.00
- 19.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.21 — today's price is already 17.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 3 | 5 | 7 | 9 | 11 |
|---|---|---|---|---|---|
| 7.3% | -7.7% | 2.2% | 9.4% | 15.0% | 19.7% |
| 12.3% | -3.4% | 7.0% | 14.5% | 20.4% | 25.3% |
| 17.3% | 0.9% | 11.8% | 19.6% | 25.7% | 30.9% |
| 22.3% | 5.2% | 16.5% | 24.7% | 31.1% | 36.4% |
| 27.3% | 9.5% | 21.3% | 29.7% | 36.4% | 42.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+400.00%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·1d ago·Positive
IBEX Limited (IBEX) Q4 2026 Earnings Call Transcript IBEX Limited (IBEX) Q4 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·1d ago·Neutral
IBEX Q4 Earnings Call Highlights IBEX NASDAQ: IBEX reported record fourth-quarter and fiscal 2026 results, supported by double-digit revenue growth, expansion in health tech and other verticals, and increasing traction for its AI agent offerings.
View source ↗ - Newsglobenewswire.com·1d ago·Negative
IBEX Reports Record Fiscal Year 2026 Financial Results, Introduces Fiscal Year 2027 Guidance WASHINGTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”) (Nasdaq: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, today announced financial results for its fourth quarter and fiscal year ended June 30, 2026.
View source ↗ - Newsglobenewswire.com·15d ago·Negative
IBEX Limited to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on September 10, 2026 WASHINGTON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”) (Nasdaq: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, today announced it will report fourth quarter and fiscal year 2026 financial results after the market close on Thursday, September 10, 2026. Management will host a conference call and webcast to discuss the Company's fina
View source ↗
Congress trades
No disclosed congressional trades in IBXNF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.